North America to dominate the
market with the rising prevalence of myelofibrosis and favorable reimbursement
scenario
Regional segmentation of the
global Myelofibrosis
Treatment Market by Coherent Market Insights comprises North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North America is
expected to dominate the global myelofibrosis treatment market owing to the
growing public awareness, high prevalence of the disease, favorable
reimbursement policies, and a higher percentage of the income spent on
healthcare. According to the American Society of Hematology 2016, myelofibrosis
is a potentially life-threatening blood cancer that affected approximately
20,000 Americans. Asia Pacific is expected to hold a large share of the global
market during the forecast period owing to increased disposable incomes, high
geriatric population, and improved healthcare facilities.
Myelofibrosis is a bone marrow
disease that interrupts the blood cells production process in the body. Fibrous
or scar tissue gets developed in the bone marrow leading to scarring causing
insufficient blood cell production. Myelofibrosis is a rare type of chronic
leukemia affecting blood production. The symptoms of myelofibrosis include
severe anemia, fatigue, weakness, and enlarged spleen. The disease is usually
found to occur in individuals over the age of 50 years. Myelofibrosis is of two
types namely, primary myelofibrosis and secondary myelofibrosis.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/721
The treatment options are scarce
but the U.S. Food and Drug Administration (FDA) approved Jakafi (Ruxolitinib)
in 2011, a drug developed by Novartis, which is the only approved product for
the treatment of myelofibrosis that forms a major line of defense against the
disease.
Increase in FDA approval of
pipeline drugs is expected to drive the market
Growing prevalence of
myelofibrosis in developing economies drives the demand for various treatment
options for myelofibrosis. The market is expected to grow owing to heavy
investments in research and development, appropriate reimbursement conditions,
and a large pool of patients living with myelofibrosis. In addition, the market
growth can be attributed to other factors including lifestyle up-gradation,
unmet medical needs of the patients, increasing incidences of genetic disorders,
and escalating smoking population. The market is expected to gain significant
traction with the medical advancements focusing patients suffering from
myelofibrosis. For instance, development of a molecule, CYT387 or Momelotinib,
by Gilead Sciences for treating primary myelofibrosis and the innovation of
current drug, ruxolitinib, by Incyte Corporation to develop a substitute dosing
strategy in patients with myelofibrosis.
However, limited awareness of the
novel therapies and high costs involved in treatment are the factors
restricting the growth of the global myelofibrosis treatment market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/myelofibrosis-treatment-market-721
Myelofibrosis Treatment Market
Taxonomy
The global myelofibrosis
treatment market is segmented on the basis of diagnosis, treatment, end user,
and geography.
Pipeline drug, Pacritinib,
developed by Biopharma reveals higher therapeutic efficacy for myelofibrosis
treatment
The key players operating in the
global myelofibrosis treatment market include Novartis, Eli Lilly, Roche, Merck
& Co., Celgene, Amgen, Bristol-Myers Squibb, Incyte Corporation, and Gilead
Sciences. The key players are focused on developing effective treatments that are
aimed at easing the patient symptoms with fewer side effects and improving the
quality of life. For instance, Biopharma developed Pacritinib in 2016, which is
proven to be more effective through the clinical trials than the FDA approved
ruxolitinib.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/721
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-173
No comments:
Post a Comment